This is a mixed bag. For a 3 year period, I am looking for those with most upside potential. Which would you advise to buy more and those to sell in order to buy more.
Thank you
Q: I am up over 100% with Moderna. I had originally purchased it for a shorter-term hold, about 6 months to 1 year, but with huge populations still to vaccinate, I'm thinking I should continue to hold. But, now, After moving from 240 to 340 in a few days, I wonder if it is too inflated. Is this hype because of the Delta variant, or is there real value in the stock at this price?
Q: Hi group assume that the variants / Corvid gets much worse - what top 3 sectors + top 3 stocks do you recommend going fwd - Thanks for your thoughts on this
Q: In answering another question you indicated price appreciation was likely already baked in for MRNA however at 6x earnings, a huge cash position, people not willing to get vaccines and the probability of ongoing covid variants, is this stock not a screaming buy? Your analysis please.
Q: If one believes in the potential importance of mRNA therapies to the future of human medicine in applications beyond COVID vaccines, which company would stand to benefit the most? Which are likely to benefit the most in the short term from COVID vaccines, or is this "baked in" for most already? Deduct points as needed and thank you for your excellent service.
Q: Haven’t seen a question since January. MDRA looks over sold and the stock has just issued a possible early technical buy signal using scholastics. More importantly this mRNA technology got another “shot in the arm” with the latest data indicting that they may work by STOPPING transmission not just mounting an immune response to decrease the course f the disease while you remain contagious. How well funded is MRNA. How is their free cash flow and their debt load. This technology keeps getting more and more exciting. Malaria, the common cold, HIV, etc!! And if is better maybe even influenza?
For the science geeks: Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening
Aaron J Tande, MD, Benjamin D Pollock, PhD, MSPH, Nilay D Shah, PhD, Gianrico Farrugia, MD, Abinash Virk, MD, Melanie Swift, MD, MPH, Laura Breeher, MD, MPH, Matthew Binnicker, PhD, Elie F Berbari, MD Author Notes
Clinical Infectious Diseases, ciab229, https://doi.org/10.1093/cid/ciab229
Published: 10 March 2021
Q: Both of these vaccine stock are having huge gains today, Jan 29, especially Novavax on it's very good 3rd trial results. Would now be a good time to enter with the whole world needing more vaccines and these two have confirmed their efficacy? Or still too speculative? Thanks for your timely guidance.
Q: We purchased ARCT at $105 US and it has dropped 50% due to underwhelming results.
It jumped 10% yesterday. Should we consider dollar cost averaging?
How would you rank the vaccine stocks in terms of growth?
Thanks for a great year.
Q: I have these 4 stocks, purchased higher than they are trading now, is there any hope they will go back up or should I just sell at a loss and take the hit? I was wondering if they may go back up with good earnings?
Q: Hi, recently PFE, AZN & Moderna have all dropped a lot from their highs in early December. Why do you think these stocks have dropped so much? Thanks.
Q: Good morning, I have a watch-list of vaccines, but it seemed like such a gamble in the past months, I didn't invest in any. Now that some are successful, I would like to have a position in at least one company. I've named a few above, but there are more. With the goal of growth in the next 1-2 years, which one or two "vaccine" stocks would you choose, and what percentage of the portfolio would you suggest as investment size. Thank-you.
Q: Moderna's stock has gone up significantly over the last few months. Is it a good time to sell? would love to hear your thoughts about it. Thank you!
Q: 5I team - I have marvelled today at the quality of your answers to questions and, in particular, options questions. Great job. My question is on methodology of "optimizing" covered call strategies and would request any reference you may have available in addition to a response.I have held MRNA and sold 109 Dec covered calls, purchased the calls when the stock went to 129, resold 125 Dec CC and am now trying to develop a strategy with the stock at 149. Is the simple and. most effective process to buy the calls back and place a stop loss position short of the current price? Again, if you have a reference to provide options in dealing with this, it would be much appreciated. Thank you
Q: Good morning 5i: I would like to have a small position in a US vaccine company. Both Moderna and Novavax had great run-ups these past few days. Should I wait for pull back or jump in? And which one would you prefer? Thanks so much.
Q: Hi 5I team.
My question is about healthcare and diversification in the space. I have been attempting to keep my position around the 16% portfolio weighting and currently hold ABBV, AMD, AMGN(4.8%), LLY(3%), PFE, MRNA, and WELL positions. Although I do not want to abandon the PFE/MRNA freight trains, I am looking at adding/shifting to what may be a longer term/higher dividend return avenue with the use of GILD(attractive entry and solid div), CRISPR(awaiting a pull back to $90 if it comes), and even MDT(under $103 if it comes)
How do you feel about this strategy and the switch out of AMGN/LLY to GILD/MDT?